626. Aggressive Lymphoma (DLBC & Other Aggressive B-Cell Non-Hodgkin Lymphomas) - Results from Prospective Clinical Trials: Incorporating novel agents & new adoptive cell therapy app

Eliza A Hawkes, Geoffrey Chong, Charmaine Smith, et al.

Authors Conclusion from the Abstract: Sequential AvR induction, R-CHOP and Av maintenance in pts with newly diagnosed DLBCL is feasible with a manageable toxicity profile and a high CR rate. Responses to AvR alone were higher than expected based on the relapsed/refractory population and may suggest superior efficacy of ICI in the frontline setting. These results support ongoing sequential studies of immune priming with PD1/PDL1 inhibition prior to R-CHOP in DLBCL.

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, et al.

Authors Conclusion from the Abstract: ViPOR is safe without unexpected toxicities observed. Most common AEs were hematologic with rare febrile neutropenia and no severe infections observed when given with G-CSF prophylaxis. ViPOR induces durable CRs without maintenance therapy, including refractory and post CAR-T pts. Molecular analyses are ongoing and will be presented at the meeting.

Giuseppe Gritti, Paula Marlton, Tycel J. Phillips, et al.

Authors Conclusion from the Abstract: Our study of the novel triplet combination, Pola-Ven-R, demonstrates a safety profile consistent with the known profiles of the individual drugs. This first report of the full efficacy population showed promising activity in a heavily pre-treated and refractory population of pts with R/R DLBCL. Further evaluation of Pola-Ven-R and the impact of consolidation therapy is warranted to address the significant unmet medical need in this patient population.

Aravind Ramakrishnan, Kirit M. Ardeshna, Connie Lee Batlevi, et al.

Authors Conclusion from the Abstract: AUTO3 at RP2D dose range of > 50 x 106 CAR T cells with D-1 pembrolizumab induces durable complete remissions. None of the patients in CR experienced severe CRS or neurotoxicities of any grade. Outpatient cohort is currently enrolling.

Rui Zhang, Yuhua Li, Sanfang Tu, et al.

Authors Conclusion from the Abstract: The results of the multi-target 4SCAR2.0 therapy for the treatment of highly resistant lymphomas have demonstrated increased safety and improved response rate with this novel approach. There is clear overall clinical benefit with the multi-target CART regimen as compared with the single CD19 CART treatment. Continued follow-up will verify whether the 4SCAR2.0 therapy regimen can achieve long term overall survival.